Luis Pérez de Llano 1 , Marc Miravitlles 2 , Rafael Golpe 1 , Francisco Javier Alvarez-Gutiérrez 3 , Carolina Cisneros 4 , Carlos Almonacid 5 , Eva Martinez-Moragon 6 , Francisco-Javier Gonzalez-Barcala 7 , David Ramos-Barbón 8 , Vicente Plaza 8 , Jose Luis Lopez-Campos 3 , Juan Pablo de-Torres 9 , Ciro Casanova 10 , Juan Luis Garcia Rivero 11 , Juan Rodriguez Hermosa 12 , Myriam Calle Rubio 12 , Juan Jose Soler-Cataluña 13 , Borja G Cosio 14
04 September 2020
Chronic airflow obstruction affects a wide range of airway diseases, the most frequent of which are asthma, COPD, and bronchiectasis; they are clearly identifiable in their extremes, but quite frequently overlap in some of their pathophysiological and clinical characteristics. This has generated the description of new mixed or overlapping disease phenotypes with no clear biological grounds. In this special article, a group of experts provides their perspective and proposes approaching the treatment of chronic airway disease (CAD) through the identification of a series of therapeutic goals (TG) linked to treatable traits (TT) – understood as clinical, physiological, or biological characteristics that are quantifiable using biomarkers. This therapeutic approach needs validating in a clinical trial with the strategy of identification of TG and treatment according to TT for each patient independently of their prior diagnosis.